<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE; <z:hpo ids='HP_0001824'>Weight loss</z:hpo> improves glycemic control, <z:chebi fb="23" ids="18059">lipid</z:chebi> profiles, and blood pressure in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>However, successful long-term <z:hpo ids='HP_0001824'>weight loss</z:hpo> is difficult for these patients, particularly those treated with insulin </plain></SENT>
<SENT sid="2" pm="."><plain>The aim of this study was to assess the effect of orlistat, a gastrointestinal lipase inhibitor, on <z:hpo ids='HP_0001824'>weight loss</z:hpo>, glycemic control, and <z:e sem="disease" ids="C0850624" disease_type="Disease or Syndrome" abbrv="">cardiovascular risk factors</z:e> in overweight or <z:mp ids='MP_0001261'>obese</z:mp> insulin-treated type 2 diabetic patients </plain></SENT>
<SENT sid="3" pm="."><plain>RESEARCH DESIGN AND METHODS: This study was a 1-year multicenter, randomized, double-blind, placebo-controlled trial of orlistat (120 mg three times a day) or placebo combined with a reduced-calorie diet in overweight or <z:mp ids='MP_0001261'>obese</z:mp> adults (BMI 28-40 kg/m(2)) with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> treated with insulin alone or combined with oral agents, but with suboptimal metabolic control (HbA(1c) 7.5-12.0%) </plain></SENT>
<SENT sid="4" pm="."><plain>Outcome measurements included changes in body weight, glycemic control, blood pressure, and serum <z:chebi fb="23" ids="18059">lipids</z:chebi> </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS; After 1 year, the orlistat group lost significantly more weight (-3.89 +/- 0.3% of baseline body weight, means +/- SE) than the placebo group (-1.27 +/- 0.3%, P &lt; 0.001) </plain></SENT>
<SENT sid="6" pm="."><plain>Orlistat treatment, compared with placebo, produced greater decreases in HbA(1c) (-0.62 +/- 0.08 vs. -0.27 +/- 0.08%, P = 0.002), fasting serum <z:chebi fb="105" ids="17234">glucose</z:chebi> (-1.63 +/- 0.3 vs. -1.08 +/- 0.3 mmol/l, P = 0.02), and the required doses of insulin and other diabetic medications </plain></SENT>
<SENT sid="7" pm="."><plain>Orlistat also produced greater improvements than placebo in serum total cholesterol (P = 0.0002) and <z:chebi fb="1" ids="47774">LDL cholesterol</z:chebi> concentrations (P = 0.001) and <z:chebi fb="15" ids="39026">LDL</z:chebi>/<z:chebi fb="17" ids="39025">HDL</z:chebi> ratio (P = 0.01) </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS; Orlistat therapy produces clinically significant <z:hpo ids='HP_0001824'>weight loss</z:hpo>, with improvements in glycemic control and <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> risk factors, in overweight or <z:mp ids='MP_0001261'>obese</z:mp> patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> who have suboptimal metabolic control with insulin therapy </plain></SENT>
</text></document>